The dosimetric effects of photon energy on the quality of prostate volumetric modulated arc therapy

Evaluation of patient-specific quality assurance for fractionated stereotactic treatment plans with 6 and 10MV photon beams in beam-matched linacs

Beam-matched linear accelerators (LA's) require accurate and precise dosimetry for fractionated stereotactic treatment. In this study, the beam data were validated by comparing the three-beam-matched LA's measured data and the vendor reference data. Upon its validation, the accuracy of the volumetric dose delivery for eighty patient-specific fractionated stereotactic treatment plans was evaluated. Measurements of the percentage depth dose (PDD), beam profiles, output factors (OFs), absolute output, and dynamic multi-leaf collimator (MLC) transmission factors for 6 MV and 10 MV flattening filter (FF) and flattening filter-free (FFF) photon beams were obtained from three-beam-matched LA's. The patient-specific quality assurance evaluation for all eighty plans was performed using PTW Octavius 1000 SRS™ array detectors for two-dimensional (2D) fluence measurement. The following 2D gamma passing criteria were used: 1%/1 mm, 2%/1 mm, 1%/2 mm, 2%/2 mm and 3%/2 mm. In all three LA's, gamma analysis for PDD and profile were above 97% with gamma criteria of 1%/1 mm. The differences OFs, absolute output, and dynamic MLC transmission factors were less than ± 1% of base value. For all eighty cases, the median passing rates on the three LA's were above 76%, 88%, 92%, 96%, and 98% for the above-mentioned gamma criteria of the three LA's. The beam-matched LA's showed good agreement between the measured and treatment planning system (TPS) calculated values for fractionated stereotactic VMAT plans with 6 MV and 10 MV (FF and FFF) photon beams. Patients can be shifted and treated on any beam-matched linac without the need of re-planning.

RapidPlan models for prostate radiotherapy treatment planning with 10-MV photon beams

Introduction:

The RapidPlan is a radiotherapy planning tool that uses a dataset of approved plans to predict the dose distribution and automatically generates the dose–volume constraints for optimisation of the new plan. This study compares three strategies of model building for the treatment of prostate cancer with the 10-MV photon beam.

Methods:

Three models for prostate treatment were compared: Model 6X, Model10X and Model6Xrefined. Model6X is already used in our department and was trained on treatment plans based on the 6-MV photon beam. Model10X was trained on treatment plans based on the 10-MV photon beam and manually optimised by an experienced medical physicist. Finally, Model6Xrefined was trained on plans automatically created by the Model6X, but using the 10-MV photon beam. The three models were used to generate 25 new plans with the 10-MV photon beam.

Results:

Model10X generated plans with 2 Gy lower mean dose to bladder-PTV and rectum-PTV volumes and 8% lower V15Gy at bladder and rectum volumes, although the number of monitor units increased by 170 on average.

Conclusions:

The model trained on manually optimised plans generated plans with higher normal tissue sparing. However, model building is a time-consuming process, so a cost–benefit balance should be performed.

VMAT for prostate cancer with 6-MV and 10-MV photons: Impact of beam energy on treatment plan quality and model-based secondary cancer risk estimates

The aim of the present study was to examine the effect of the photon beam energy on the volumetric modulated arc therapy (VMAT) plan quality for prostate cancer and on the risk of secondary carcinogenesis. Separate VMAT plans with 6-MV and 10-MV photons were created for 11 low-risk patients with prostate cancer. The prescribed tumor dose was 70 Gy delivered in 28 fractions. The normal tissue integral dose and parameters associated with planning target volume and organs at risk were determined by the treatment planning data. A non-linear mechanistic model considering the effects of tumor dose fractionation and cell proliferation was employed for estimating the patient-specific lifetime attributable risk (LAR) for bladder and rectal cancer induction. Data from differential dose-volume histograms were used for these risk assessments. The mean values of the planning parameters from 6-MV treatment plans differed by 0.2-3.4% from those associated with irradiation using 10-MV photons. The LAR range for developing secondary bladder malignancies varied between 0.041 and 0.129% by the patient under investigation and the beam energy used. The corresponding range for the appearance of rectal malignant diseases was 0.047-0.153%. The mean percentage difference between the bladder cancer risks from VMAT with 6-MV and 10-MV photons was 2.6±2.3%. The corresponding difference for secondary rectal malignancies was 0.7±0.6%. Therefore, VMAT for prostate cancer with both 6-MV and 10-MV photons leads to clinically equivalent treatment plans and to similar secondary bladder and rectal cancer risks.

Evaluation of mixed energy partial arcs for volumetric modulated arc therapy for prostate cancer

PURPOSE

The purpose of this work was to investigate the dosimetric impact of mixed energy (6-MV, 15-MV) partial arcs (MEPAs) technique on prostate cancer VMAT plans.

METHODS

This work involved prostate only patients, planned with 79.2 Gy in 44 fractions to the planning target volume (PTV). Femoral heads, bladder, and rectum were considered organs at risk. This study was performed in two parts. For each of the 25 patients in Part 1, two single-energy single-arc plans, a 6 MV-SA plan and a 15 MV-SA plan, and a third MEPA plan involving composite of 6-MV anterior-posterior partial arcs and a 15-MV lateral partial arc weighted 1:2 were created. The dosimetric difference between MEPA(6/15 MV 1:2 weighted) and 6 MV-SA plans, and MEPA(6/15 MV 1:2 weighted) and 15 MV-SA plans were measured. In the Part 2 of this study, a second MEPAs plan (6 MV anterior-posterior arcs and 15 MV lateral arcs weighted 1:1), (MEPA 6/15 MV 1:1 weighted), was generated for 15 patients and compared only with two single-energy partial arcs plans, a 6 and a 15 MV-PA, to investigate the influence of the energy only. Dosimetric parameters of each structure, total monitor-units (MUs), homogeneity index (HI), and conformity number (CN) were analyzed.

RESULTS

In Part 1, no statistically significant differences were observed for mean dose to PTV and CN for MEPAs (6/15 MV 1:2 weighted) vs 6 and 15 MV-SA. MEPAs (6/15 MV 1:2 weighted) increased HI compared to 6 and 15 MV-SA (P < 0.0005; P < 0.0005). MEPAs (6/15 MV 1:2 weighted) produced significantly lower mean doses to rectum, bladder, and MUs/fraction, but higher mean doses to femoral heads, compared to 6 MV-SA (P < 0.0005) and 15 MV-SA (P < 0.0005). The results of Part 2 of this study showed that, in comparison to 6 and 15 MV-PA, MEPAs (6/15 MV 1:1 weighted) plans significantly improved CNs (P < 0.0005; P < 0.0005) and produced significantly lower mean doses to the rectum and bladder (P < 0.0005; P < 0.0005). While mean doses to the PTV and femoral heads of MEPAs (6/15 MV 1:1 weighted) plans were statistically comparable to 6 MV-PA (P > 0.05), MEPAs (6/15 MV 1:1 weighted) increased mean doses to left (P = 0.04) and right (P = 0.04) femoral heads compared to 15 MV-PA. MEPAs (6/15 MV 1:1 weighted) resulted in significantly lower total MUs compared to 6 MV-PA (P < 0.0005) and 15 MV-PA (P = 0.04).

CONCLUSION

The study for prostate radiotherapy demonstrated that a choice of MEPAs for VMAT has the potential to minimize doses to OARs and improve dose conformity to PTV, at the expense of a moderate increase in mean dose to the femoral heads.

Impact of nominal photon energies on normal tissue sparing in knowledge-based radiotherapy treatment planning for rectal cancer patients

The interactive adjustment of the optimization objectives during the treatment planning process has made it difficult to evaluate the impact of beam quality exclusively in radiotherapy. Without consensus in the published results, the arbitrary selection of photon energies increased the probability of suboptimal plans. This work aims to evaluate the dosimetric impact of various photon energies on the sparing of normal tissues by applying a preconfigured knowledge-based planning (RapidPlan) model to various clinically available photon energies for rectal cancer patients, based on model-generated optimization objectives, which provide a comparison basis with less human interference. A RapidPlan model based on 81 historical VMAT plans for pre-surgical rectal cancer patients using 10MV flattened beam (10X) was used to generate patient-specific objectives for the automated optimization of other 20 patients using 6X, 8X, 10X (reference), 6MV flattening-filter-free (6F) and 10F beams respectively on a TrueBeam accelerator. It was observed that flattened beams produced very comparable target dose coverage yet the conformity index using 6F and 10F were clinically unacceptable (>1.29). Therefore, dose to organs-at-risk (OARs) and normal tissues were only evaluated for flattened beams. RapidPlan-generated objectives for 6X and 8X beams can achieve comparable target dose coverage as that of 10X, yet the dose to normal tissues increased monotonically with decreased energies. Differences were statistically significant except femoral heads. From the radiological perspective of view, higher beam energy is still preferable for deep seated tumors, even if multiple field entries such as VMAT technique can accumulate enough dose to the target using lower energies, as reported in the literature. In conclusion, RapidPlan model configured for flattened beams cannot optimize un-flattened beams before adjusting the target objectives, yet works for flattened beams of other energies. For the investigated 10X, 8X and 6X photons, higher energies provide better normal tissue sparing.

[Which photon energy for intensity-modulated radiotherapy and volumetric-modulated arctherapy in 2019?]

For more than a decade, the majority of radiation oncology centres have been delivering intensity-modulated radiotherapy (then volumetric-modulated arctherapy) with 6 MV photons as their standard of care. This « dogma » had been supported by the usual absence of dosimetric advantages with high-energy photons (15 to 18 MV or more), at least for the planning target volume and the dose received by the adjacent organs at risk, and by the neutron component as soon as the photon energy exceeds 10 MV. Recent data could question such a dogma. First, in 2019, one cannot avoid taking into account the integral dose, delivered outside the treated volume. Actually, most available data show that integral dose is higher with low energy photons (as 6 MV) than with higher energies. Moreover, recent studies have shown that the neutron component at high energies may have been overestimated in the past; in fact, the neutron dose appears to be lower, and sometimes much lower, than the dose we accept for imaging. Finally, a few cohort studies did not show any increase in second cancers incidence after high-energy photon radiotherapy. In such a context, the American Association of Physicists in Medicine (AAPM) TG 158 document, released a few months ago, clearly states that there is a trade-off between high- and low-energy treatments. High-energy therapy is associated with neutron production, while low-energy therapy results in higher stray photon dose. According to the AAPM, « the optimal energy is likely an intermediate such as 10 MV ».

Dosimetric influence of photon beam energy and number of arcs on volumetric modulated arc therapy in carcinoma cervix: A planning study

AIM

Aim of the present study was to compare the dosimetric impact of different photon beam energies and number of arcs in the treatment of carcinoma cervix.

BACKGROUND

Carcinoma cervix is a common cancer in women worldwide with a high morbidity rate. Radiotherapy is used to treat such tumours. Volumetric Modulated Arc Therapy (VMAT) is considered superior to other techniques with multiple arcs and energies.

MATERIALS AND METHODS

Twenty patients with carcinoma cervix underwent radiotherapy in a prospective observation study conducted at our institute. Volumetric modulated arc plans with 6 MV, 10 MV and 15 MV photon energies using single arc (SA) and dual arc (DA) were generated. Several physical indices for planning target volume (PTV) like V95%, V100%, V110%, D98%, D50%, D2% and total number of MUs were compared. Normal Tissue Integral Dose (NTID) and dose to a shell structure PHY2.5 and PHY5.0 were analyzed.

RESULTS

Comparable dose coverage to PTV was observed for all the energies and arcs. CI for DA6MV (1.095) was better than SA6MV (1.127), SA10MV (1.116) and SA15MV (1.116). Evaluated parameters showed significant reduction in OAR doses. Mean bladder dose for DA6MV (41.90 Gy) was better than SA6MV (42.48 Gy), SA10MV (42.08 Gy) and SA15MV (41.93 Gy). Similarly, p-value for the mean rectal dose calculated was 0.001 (SA6 vs 15), 0.013 (DA6 vs 10) and 0.003 (DA6 vs 15) and subsequently favoured DA6MV. Difference in NTID was very small.

CONCLUSIONS

The study showed no greater advantage of higher energy, and DA VMAT plan with 6 MV photon energy was a good choice of treatment for carcinoma cervix as it delivered a highly homogeneous and conformal plan with superior target coverage and better OAR sparing.

The dosimetric significance of using 10 MV photons for volumetric modulated arc therapy for post-prostatectomy irradiation of the prostate bed

BACKGROUND

The purpose of the study was to analyse the dosimetric differences when using 10 MV instead of 6 MV for VMAT treatment plans for post-prostatectomy irradiation of the prostate bed.

METHODS AND MATERIALS

Ten post-prostatectomy prostate bed irradiation cases previously treated using 6 MV with volumetric modulated arc therapy (VMAT) were re-planned using 10 MV with VMAT. Prescription dose was 66.6 Gy with 1.8 Gy per fraction for 37 daily fractions. The same structure set, number of arcs, field sizes, and minimum dose to the Planning Target Volume (PTV) were used for both 6 MV and 10 MV plans. Results were collected for dose to Organs at Risk (OAR) constraints, dose to the target structures, number of monitor units for each arc, Body V5, Conformity Index, and Integral Dose. The mean values were used to compare the 6 MV and 10 MV results. To determine the statistical significance of the results, a paired Student t test and power analysis was performed.

RESULTS

Statistically significant lower mean values were observed for the OAR dose constraints for the rectum, bladder-Clinical Target Volume (bladder-CTV), left femoral head, and right femoral head. Also, statistically significant lower mean values were observed for the Body V5, Conformity Index, and Integral Dose.

CONCLUSIONS

Several dosimetric benefits were observed when using 10 MV instead of 6 MV for VMAT based treatment plans. Benefits include sparing more dose from the OAR while still maintaining the same dose coverage to the PTV. Other benefits include lower Body V 5,Conformity Index, and Integral Dose.

The dosimetric impact of different photon beam energy on RapidArc radiotherapy planning for cervix carcinoma

The main purpose of this study is to know the effect of three different photon energies viz., 6, 10, and 15 mega voltage (MV) on RapidArc (RA) planning for deep-seated cervix tumor and to develop clinically acceptable RA plans with suitable photon energy. RA plans were generated for 6, 10, and 15 MV photon energies for twenty patients reported with cervix carcinoma. RA plans were evaluated in terms of planning target volume (PTV) coverage, dose to organs at risk (OARs), conformity index (CI), homogeneity index (HI), gradient measure, external volume index of dose distribution produced, total number of monitor units (MUs), nontumor integral dose (ID), and low dose volume of normal tissue. A two-sample paired t-test was performed to compare the dosimetric parameters of RA plans. Irrespective of photon energy used for RA planning, plans were dosimetrically similar in terms of PTV coverage, OARs sparing, CI and HI. The numbers of MUs were 13.4 ± 1.4% and 18.2 ± 1.5% higher and IDs were 2.7 ± 0.8% and 3.7 ± 0.9% higher in 6 MV plans in comparison to that in the 10 and 15 MV plans, respectively. V1Gy, V2Gy, V3Gy, and V4Gy were higher in 6 MV plans in comparison to that in 10 and 15 MV plans. Based on this study, 6 MV photon beam is a good choice for RA planning in case of cervix carcinoma, as it does not deliver additional exposure to patients caused by photoneutrons produced in high energy beams.